![]() ![]() Le Parlement européen et le Conseil sont convenus qu'au considérant 17 du règlement 2020/1043, la procédure d'approbation actuelle des OGM n'est pas bien adaptée pour améliorer la santé publique. ![]() Premièrement, la majorité des vaccins en cours de développement relèveraient de la directive 2001/18 relative à la dissémination d'OGM dans l'environnement. La pandémie de Covid‐19 pourrait agir comme un déclencheur fort nécessaire pour changer la réglementation de l'Union européenne concernant les organismes génétiquement modifiés (OGM). As the Covid‐19 crisis drains government budgets, views around GMOs in the EU may change in the light of positive experiences from the approval of Covid‐19 vaccines. Modern plant breeding has the potential to provide less expensive solutions to support vulnerable groups. Secondly, several studies have shown that the Covid‐19 crisis reduces the purchasing power of households and increases their vulnerability in the case of food shortages and consequent increases in food prices further exacerbate the nutritional problems of vulnerable groups. This was driven in particular by the need for vaccine approval in the context of the Covid‐19 pandemic and a more appropriate approval procedure would be applied. The European Parliament and Council agreed that, in Recital 17 of Regulation 2020/1043, the current approval procedure for GMOs is not well‐suited to improving public health. Firstly, the majority of vaccines under development would fall under Directive 2001/18 on the release of GMOs into the environment. There are two main reasons for this potential development. The Covid‐19 pandemic has the potential to act as a much‐needed trigger for changes to the European Union regulations around genetically modified organisms (GMOs). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |